YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

The Blood-Brain Barrier Permeability and Pharmacokinetics of Nitrone Based Spin Trapping Agent, $\alpha$-Phenyl-n-tert-Butyl Nitrone (PBN) in Rats

흰쥐에서 nitrone계 항산화제인 $\alpha$-phenyl-n-tert-butyl nitrone(PBN)의 뇌 투과성 및 체내동태

  • 이나영 (숙명여자대학교 약학대학) ;
  • 강영숙 (숙명여자대학교 약학대학)
  • Published : 2002.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

The nitrone-based free radical trapping reagent, $\alpha$-phenyl-n-tert-butyl nitrone (PBN) has been proposed as therapeutic agent for stroke. We used this for model drug of development of new drug for neuroprotection. The purpose of this study was to evaluate the blood-brain barrier (BBB) permeability of PBN in Sprague-Dawly (SD) rats. The BBB transport of PBN was investigated in SD rats using internal carotid artery perfusion (ICAP) method at a rate of 4 mι/min for 15 second. We also obtained pharmacokinetic parameters of PBN using single intravenous injection technique. When we estimated BBB permeability of PBN with ICAP method, the brain volume of distribution of PBN was 60.0 $\pm$ 12.0 $\mu\textrm{g}$/ι. The brain uptake of PBN after IV injection at 120 min was 0.15 $\pm$ 0.01%ID/g. The PBN was transported to the brain through the BBB well in rats, because PBN is small molecule (MW 177) and lipid-soluble (log P 1.23) compound.

Keywords

References

  1. Facchinetti F., Dawson V. L. and Dowson T. M. : Free radicals as mediators of neuronal injury. Cell. Mol. Neurobiol. 18, 667 (1998) https://doi.org/10.1023/A:1020221919154
  2. Knecht K. T. and Mason R. P. : In vivo spin trapping of xenobiotic free radical metabolites. Arch. Biochem. Biophys. 303, 185 (1993) https://doi.org/10.1006/abbi.1993.1272
  3. Phillis J. and Clough-Helfman C. : Protection from cerebral ischemic injury in gerbils with the spin trap agent ${\alpha}$-phenyl-n-tert-butyl nitrone (PBN). Neurosci. Lett. 116, 315 (1990) https://doi.org/10.1016/0304-3940(90)90093-O
  4. Cao X. and Phillis J. : ${\alpha}$-phenyl-n-tert-butyl nitrone reduced cortical infarct and edema in rats subjected to focal ischemia. Brain Res. 644, 267 (1994) https://doi.org/10.1016/0006-8993(94)91689-6
  5. Zhao Q., Pahlmark K., Smith M. L. and Siesjo B. K. : Delayed treatment with the spin trap ${\alpha}$-phenyl-n-tert-butyl nitrone (PBN) reduces infarct size following transient middle cerebral artery occlusion in rats. Acta Physiol. Scand. 152, 349 (1994). https://doi.org/10.1111/j.1748-1716.1994.tb09816.x
  6. He Q. P., Smith M. L., Li P. A. and Siesjo B. K. : Necrosis of the substania nigra, pars reticulate, in flurothyl-induced status epilepticus is ameliorated by spin trap ${\alpha}$-phenyl-n-tert-butyl nitrone. Free Radical Biol. Med. 22, 917 (1997) https://doi.org/10.1016/S0891-5849(96)00478-9
  7. Edumatsu R., Mori A. and Packer L. : The spin trap ${\alpha}$-phenyl n-tert-butyl nitrone prolongs the life span of the senescence accelerated mouse. Biochem. Biophys. Res. Commun. 211, 847 (1995) https://doi.org/10.1006/bbrc.1995.1889
  8. Takasato Y., Rapoport S. I. and Smith Q. T. : An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol. 247, H484 (1984)
  9. Kang YS., Saito Y. and Pardridge W.M. : Pharmacokinetics of [$^{3}H$]biotin bound to different avidin analogues. J. Drug Target. 3, 159 (1995). https://doi.org/10.3109/10611869509059215
  10. Gibaldi, M. and Perrier, D. : Pharmacokinetics, Marcel Dekker Inc., New York p. 1 (1982)
  11. 강영숙, 김유정 : 생쥐에 있어서 약물의 혈액-뇌관문 투과성 평가를 위한 간편한 in vivo 방법. 약제학회지 30, 99 (2000)
  12. Levin VA. : Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med. Chem. 23, 682 (1982) https://doi.org/10.1021/jm00180a022
  13. Wu D., Kang Y. S, Bickel U. and Pardridge W. M. : Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine. Drug Metabol. Distrib. 25, 768 (1997)
  14. Kang Y. S and Pardridge W. M. : Use of neutral avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate. J. Pharm. Exp. Ther. 269, 344 (1994)